氨氯地平联合阿伐他汀治疗高血压合并高血脂症疗效观察

目的探讨高血压合并高血脂症患者给予氨氯地平联合阿伐他汀治疗效果。方法选取2010年1月~2011年12月间收治的100例高血压合并高血脂症患者为研究对象,将其按照随机数字法分为对照组和研究组,对照组给予常规的氨氯地平治疗,研究组给予氨氯地平联合阿伐他汀治疗,观察两组的临床治疗效果。结果通过对两组的治疗效果比较,研究组的总有效率为94.0%,对照组的总有效率为72.0%,研究组的临床治疗总有效率明显优于对照组,差异有统计学意义(P0.05)。治疗前后对照组和研究组的SBP和DBP比较差异无统计学意义(P0.05);治疗后研究组和对照组的SBP和DBP较治疗前均有明显的改善,且组间的数据比较差异有统计学意义(P0.05)。治疗前研究组和对照组的LDL-C、HDL-C、TG和TC比较差异无统计学意义(P0.05);治疗后研究组和对照组的LDL-C、HDL-C、TG和TC较治疗前均有明显的改善,且组间的数据比较差异有统计学意义(P0.05)。对照组不良反应发生率为12.0%,研究组不良反应发生率为16.0%,两组的数据比较差异无统计学意义(P0.05)。结论高血压合并高血脂症患者给予氨氯地平联合阿伐他汀治疗效果显著,治疗安全性高,值得临床应用与推广。

Effect of amlodipine plus atorvastatin calcium on hypertension patients complicated with hyperlipidemia

Objective To investigate the effect of amlodipine plus atorvastatin calcium on hypertension patients complicated with hyperlipidemia. Methods From January 2010 to December 2011, 100 hypertension cases complicated with hyperlipidemia randomly divided into a control group received conventional amlodipine treatment, and observation group received amlodipine plus atorvastatin calcium therapy.The clinical effect. Results By comparing the therapeutic effect of two groups, the study group clinical total effective rate was 94.0% in the control group total effective rate was 72.0%, the total effective rate in observation group was significantly better than the control group（P〈0.05）. Before and after treatment thee SBP and DBP showed no significant difference（P〈0.05）, the levels of SBP and DBP after treatment compared with that before treatment were significantly improved.. Before treatment, the levels of LDL-C, HDL-C, TG and TC in observation and control group showed no significant difference（P〈0.05）.The levels of LDL-C, HDL-C, TG and TC both in observation and control group were significantly improved. The adverse reactions occurred to those in control group was 12.0% and 16.0% in observation group, without significant difference（P〈0.05）. Conclusion Amlodipine plus atorvastatin calcium is effective for treatment of hypertension cases complicated with hyperlipidemia and the regimen is safe and worthy of clinical application.